Company news
Biomea Fusion, Inc. (NASDAQ:BMEA) news
Biomea Fusion, Inc. news releases on 6ix. Latest, Sep 23, 2026: Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Press releases & updates
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
September 23, 2026
Biomea Fusion to Participate in Upcoming Investor Conferences
September 3, 2026
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
August 24, 2026
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
August 13, 2026
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 5, 2026
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 5, 2026
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
June 3, 2026
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
May 11, 2026
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
May 5, 2026
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
April 27, 2026
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 30, 2026
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
December 9, 2025
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 5, 2025
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 1, 2025
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 1, 2025
Biomea Fusion to Participate at Upcoming Investor Conferences
November 24, 2025
Biomea Fusion to Participate at Jefferies London Healthcare Conference
November 10, 2025
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
November 5, 2025
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 4, 2025
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
October 30, 2025
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
October 27, 2025
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
October 21, 2025
Biomea Fusion Announces Pricing of Public Offering of Securities
October 7, 2025
Biomea Fusion Announces Proposed Public Offering of Securities
October 6, 2025
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
October 6, 2025
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
September 30, 2025
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
September 16, 2025
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 5, 2025
Biomea Fusion Appoints Julianne Averill to its Board of Directors
July 24, 2025
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
June 23, 2025
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
June 18, 2025
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
June 13, 2025
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
May 14, 2025
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
May 5, 2025
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 1, 2025
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
March 31, 2025
Biomea Fusion Announces Leadership Transition
March 25, 2025
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
March 24, 2025
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 2, 2025
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
February 27, 2025
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
January 6, 2025
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
December 16, 2024
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
December 15, 2024
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 11, 2024
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 8, 2024
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 5, 2024